Andrew Hill

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 8

Top Topics

Men Who Have Sex With Men

Antiretroviral Therapy

Human Immunodeficiency Virus

Top Venues

Open forum infectious diseases

The Journal of antimicrobial chemotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Andrew Hill, Jacob Levi, Cassandra Fairhead, Victoria Pilkington, Junzheng Wang, Madison Johnson, Jevon Layne, David Roberts, Joseph Fortunak
Lenacapavir to prevent HIV infection: current prices versus estimated costs of production. The Journal of antimicrobial chemotherapy (2024)
Andrew Hill, Tamara Tovar Sanchez, Eric Delaporte, Simiso Mandisa Sokhela, Bryony Simmons, Charles Kouanfack, Kaitlyn Mccann, Jacob Levi, Cassandra Fairhead, Willem Daniel Francois Venter
Low CD4 counts predict excessive weight gains during first-line treatment for HIV. The Journal of antimicrobial chemotherapy (2024)
Andrew Hill, Tamara Tovar Sanchez, Eric Delaporte, Simiso Mandisa Sokhela, Bryony Simmons, Charles Kouanfack, Kaitlyn Mccann, Jacob Levi, Cassandra Fairhead, Willem Daniel Francois Venter
Low CD4 counts predict excessive weight gains during first-line treatment for HIV. The Journal of antimicrobial chemotherapy 79 (9) (2024)
Toby Pepperrell, Andrew Hill, Samuel Cross
Lower Prevalence Countries Outside of South-Eastern Africa Now Have the Fastest Growing HIV Epidemic. Open forum infectious diseases 11 (7) (2024)
Toby Pepperrell, Andrew Hill, Samuel Cross
Lower Prevalence Countries Outside of South-Eastern Africa Now Have the Fastest Growing HIV Epidemic. Open forum infectious diseases 11 (7) (2024)
Mireille Mpoudi-Etame, Tamara Tovar Sanchez, Marwân-Al-Qays Bousmah, Pierrette Omgba Bassega, Justin Olinga, Eric Mimbe, Michel Foalem, Camille Chiep, Serge Edimo, Marie Varloteaux, Raphaël Pelloquin, Nadine Lamare, Sylvie Boyer, Martine Peeters, Jacques Reynes, Alexandra Calmy, Andrew Hill, Eric Delaporte, Charles Kouanfack, null null
Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study. Open forum infectious diseases 10 (12) (2023)
Mireille Mpoudi-Etame, Tamara Tovar Sanchez, Marwân-Al-Qays Bousmah, Pierrette Omgba Bassega, Justin Olinga, Eric Mimbe, Michel Foalem, Camille Chiep, Serge Edimo, Marie Varloteaux, Raphaël Pelloquin, Nadine Lamare, Sylvie Boyer, Martine Peeters, Jacques Reynes, Alexandra Calmy, Andrew Hill, Eric Delaporte, Charles Kouanfack, null null
Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study. Open forum infectious diseases 10 (12) (2023)
Mireille Mpoudi-Etame, Tamara Tovar Sanchez, Marwân-Al-Qays Bousmah, Pierrette Omgba Bassega, Justin Olinga, Eric Mimbe, Michel Foalem, Camille Chiep, Serge Edimo, Marie Varloteaux, Raphaël Pelloquin, Nadine Lamare, Sylvie Boyer, Martine Peeters, Jacques Reynes, Alexandra Calmy, Andrew Hill, Eric Delaporte, Charles Kouanfack, null null
Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study. Open forum infectious diseases 10 (12) (2023)